secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001213900-24-042322
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax Q1 2024 operating loss $3.2M, cash $1.9M; Probudur study shows tolerability
--------------------------------------------------------------------------------

- Operating loss of $3.2M compares to $1.5M in Q1 2023, driven by higher G&A and R&D spend.
- Cash at March 31, 2024 was approximately $1.9M.
- Probudur maximum tolerated dose study: all doses well-tolerated, no noteworthy effects on body weight or clinical parameters.
- Litigation settlement with Sorrento Therapeutics approved by bankruptcy court; initial payment made March 18, 2024.
- Pilot study of Probudur in rat model showed reduction in incision-induced pain behaviors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/0001213900-24-042322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024042322/ea0205936-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-042322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer